O'Neill Gilmore Neil sold $51K of EDIT

O'Neill Gilmore Neil (CEO) sold 21,164 shares of Editas Medicine, Inc. (EDIT) at $2.42 on 2026-11-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · O'Neill Gilmore Neil
Published Nov 13, 2026, 9:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EDIT
Bearish
medium confidence
Mentioned
$EDIT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EDITBearishLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock materially.

02

Market read

A small insider sale with limited market impact; traders may note but no immediate action required.

03

What to watch

The CEO's holdings remain substantial, reducing the significance of the sale.

Relevance 2/10Novelty 2/10Timing: after-hours filing on 2026-11-13

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan sale is pre‑arranged and often unrelated to current market conditions.

Company-level read

Ticker impact

$EDITBearishMedium confidence
Context

CEO O'Neill Gilmore Neil sold 21,164 shares for $51,121 via a 10b5-1 plan, reducing his stake to 265,592 shares.

Expected impact

likely slight pressure as the market prices in the insider sell.

Evidence & confidence

The sale is small relative to float and disclosed via a pre‑arranged plan, limiting actionable impact.

Market effects

Minimal effect on the broader biotech sector.

None

None

Counterpoint

The sale could be routine and not indicative of future performance.

Key entities

  • Editas Medicine, Inc.

    Biotech firm developing CRISPR‑based gene editing therapies.

  • O'Neill Gilmore Neil

    CEO of Editas Medicine.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EDITMed

Editas Medicine Reports Q3 2026 Results, $10.4M Revenue and $23.4M Net Loss

Editas Medicine reported Q3 2026 revenue of $10.4M and a net loss of $23.4M, improving from the same period last year. The company received Australian clearance for its Phase 1/2 Strive study of EDIT-401 and expects to dose the first patients this year. Editas anticipates its cash resources will fund operations into the second half of 2028. Preclinical data for EDIT-401 showed promising results in non-human primates.

$PRMEHighAI 8/10

StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance

Shares of gene editing therapy companies surged this week due to positive data from the ESGCT Congress and FDA draft guidance for personalized gene therapies. Prime Medicine (PRME) rose 29%, Beam Therapeutics (BEAM) 13%, Editas Medicine (EDIT) 11%, and Intellia Therapeutics (NTLA) 11%. The FDA's guidance aims to streamline approvals for individualized genome editing products. Analysts view the developments positively, anticipating continued momentum.

$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.